Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer

Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) significantly improve progression‐free survival and have become the standard therapy for estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer patients. Treatment surveillance by radiological imaging has...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Yoon Ming, Shibayama, Tomoko, Chan, Hiu Ting, Otaki, Masumi, Hara, Fumikata, Kobayashi, Takayuki, Kobayashi, Kokoro, Hosonaga, Mari, Fukada, Ippei, Inagaki, Lina, Ono, Makiko, Ito, Yoshinori, Takahashi, Shunji, Ohno, Shinji, Ueno, Takayuki, Nakamura, Yusuke, Low, Siew‐Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128178/
https://www.ncbi.nlm.nih.gov/pubmed/35201661
http://dx.doi.org/10.1111/cas.15304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128178/
https://www.ncbi.nlm.nih.gov/pubmed/35201661
http://dx.doi.org/10.1111/cas.15304

Ejemplares similares